NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$2.0b

Last Updated

2021/05/06 23:41 UTC

Data Sources

Company Financials +

Executive Summary

Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. More Details


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has Aurora Cannabis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACB is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ACB's weekly volatility has decreased from 21% to 14% over the past year.


Market Performance


7 Day Return

-6.3%

ACB

-0.3%

CA Pharmaceuticals

0.8%

CA Market


1 Year Return

-10.8%

ACB

100.4%

CA Pharmaceuticals

37.1%

CA Market

Return vs Industry: ACB underperformed the Canadian Pharmaceuticals industry which returned 103.1% over the past year.

Return vs Market: ACB underperformed the Canadian Market which returned 37.1% over the past year.


Shareholder returns

ACBIndustryMarket
7 Day-6.3%-0.3%0.8%
30 Day-9.2%-8.8%1.4%
90 Day-37.1%-22.3%7.6%
1 Year-10.8%-10.8%100.4%100.4%41.5%37.1%
3 Year-88.8%-89.2%-54.5%-55.2%29.5%17.1%
5 Year89.2%82.3%266.1%263.5%58.9%35.1%

Long-Term Price Volatility Vs. Market

How volatile is Aurora Cannabis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aurora Cannabis undervalued compared to its fair value and its price relative to the market?

39.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACB (CA$10.28) is trading below our estimate of fair value (CA$16.85)

Significantly Below Fair Value: ACB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACB is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: ACB is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACB is good value based on its PB Ratio (0.9x) compared to the CA Pharmaceuticals industry average (2.8x).


Future Growth

How is Aurora Cannabis forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

43.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACB's revenue (24.8% per year) is forecast to grow faster than the Canadian market (7.3% per year).

High Growth Revenue: ACB's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACB's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Aurora Cannabis performed over the past 5 years?

-84.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACB is currently unprofitable.

Growing Profit Margin: ACB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACB is unprofitable, and losses have increased over the past 5 years at a rate of 84.8% per year.

Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).


Return on Equity

High ROE: ACB has a negative Return on Equity (-109.66%), as it is currently unprofitable.


Financial Health

How is Aurora Cannabis's financial position?


Financial Position Analysis

Short Term Liabilities: ACB's short term assets (CA$742.6M) exceed its short term liabilities (CA$149.8M).

Long Term Liabilities: ACB's short term assets (CA$742.6M) exceed its long term liabilities (CA$483.2M).


Debt to Equity History and Analysis

Debt Level: ACB's debt to equity ratio (18.8%) is considered satisfactory.

Reducing Debt: ACB's debt to equity ratio has reduced from 159.2% to 18.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Aurora Cannabis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACB's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Miguel Martin (48 yo)

0.67

Tenure

Mr. Miguel Martin serves as Chief Executive Officer and Director at Aurora Cannabis Inc. since September 8, 2020 and also was its Chief Commercial Officer since July 06, 2020. He serves as the President of...


Leadership Team

Experienced Management: ACB's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: ACB's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 80.9%.


Top Shareholders

Company Information

Aurora Cannabis Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aurora Cannabis Inc.
  • Ticker: ACB
  • Exchange: TSX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.036b
  • Shares outstanding: 198.02m
  • Website: https://auroramj.com

Number of Employees


Location

  • Aurora Cannabis Inc.
  • Edmonton International Airport
  • 4818 31 Street East
  • Edmonton
  • Alberta
  • T9E 0V6
  • Canada

Listings


Biography

Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including fa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/06 23:41
End of Day Share Price2021/05/06 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.